The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women
Tóm tắt
Từ khóa
Tài liệu tham khảo
UNAIDS. UNAIDS data 2018. https://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf. Accessed 05 Jul 2020.
WHO. Guidelines on the public health response to pretreatment HIV drug resistance. July 2017. https://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055-eng.pdf;jsessionid=C3EE93B78182C3FD322531B461143CBA?sequence=1. Accessed 01 Feb 2019.
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018;379(10):979–81.
WHO. Statement on dolutegravir. https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf. Accessed 01 Feb 2019.
Dodoo A, Hugman B. Risk perception and communication in sub-Saharan Africa. Drug Saf. 2012;35(11):1041–52.
Campbell WH, Califf RM. Improving communication of drug risks to prevent patient injury: proceedings of a workshop. Pharmacoepidemiol Drug Saf. 2003;12(3):183–94.
Isah AO, Pal SN, Olsson S, et al. Specific features of medicines safety and pharmacovigilance in Africa. Ther Adv Drug Saf. 2012;3(1):25–34.
Nwaka S, Ochem A, Besson D, et al. Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent. BMC Int Health Hum Rights. 2012;12(1):11.
Castelnuovo B, Kiragga A, Afayo V, et al. Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in sub-Saharan Africa. PLoS One. 2012;7(12):e51631.
The Antiretroviral Pregnancy Registry. http://www.apregistry.com/. Accessed 05 Jul 2020.
Sweden K, Kiiza D, Laker E, et al. High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily. J Antimicrob Chemother. 2018;73(11):3158–61.
Edwards A, Elwyn G. Understanding risk and lessons for clinical risk communication about treatment preferences. Qual Health Care. 2001;10(Suppl. 1):i9–13.
AfroCab. IAS2018: communique of the Kigali dolutegravir stakeholder meeting of African women living with HIV, hosted by AfroCAB. 2018, Kigali, Rwanda 13–14 July 2020.
Trust S. Building a safe house on firm ground: key findings from a global values and preferences survey regarding the sexual and reproductive health and human rights of women living with HIV. Geneva: WHO; 2014.
Thomson KA, Dhanireddy S, Andrasik M, et al. Fertility desires and preferences for safer conception strategies among people receiving care for HIV at a publicly-funded clinic in Seattle, WA. AIDS Care. 2018;30(1):121–9.
Finocchario-Kessler S, Dariotis JK, Sweat MD, et al. Do HIV-infected women want to discuss reproductive plans with providers, and are those conversations occurring? AIDS Patient Care STDS. 2010;24(5):317–23.
Schwartz SR, Rees H, Mehta S, et al. High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. PLoS One. 2012;7(4):e36039.
Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019;381(9):827–40.
WHO. Update of recommendations on first- and second-line antiretroviral regimes. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1. Accessed 24 Sept 2019.